Massachusetts-based life science research firm Rubix Life Sciences has launched a therapeutic division dedicated to infectious and neurodegenerative diseases.
In a declarationRubix Founder and CEO Reginald Swift said the company has invested in new facilities and expanded its clinical research capacity in the disciplines mentioned. The aim is to expand its growing portfolio of products for decisive and inclusive health outcomes in various disease states over the following months.
Rubix LS is a culture-centric research company committed to including minority datasets in every phase of the life science development system. Through virtual clinical trials, the company strives to link its scientific and operational expertise to personalized solutions that will improve the quality of life of minority groups.
The news follows shortly after the news that Rubix is in the process of build a 40,000 square foot site in Lawrence focus on the clinical therapeutic research needs of under-represented communities. It will include a 10,000 square foot fully automated digital experience care center for launching virtual clinical trials. The rest of the space will house a laboratory specially equipped for in-depth genetic research.
This expansion is expected to create some 300 new, well-paying jobs over the next three years. In addition, it will allow the company to support the community and its surroundings, which are 80% Hispanic and Latino.
According to the 2020 census, the two demographics represent 18.7% of the U.S. population but account for 51.1% of the country’s growth. However, clinical representation dating back to 1983 to 2020 had less than 2.7% of their representation in research.
“The health innovation sector has incredible potential to advance health equity, but most models in the industry do not incorporate an equity lens – risking automation, upgrading. ‘scale and exacerbation of health, racial and social inequalities,’ said Health Equity Director Aletha Maybank, MD, MPH, of the American Medical Association.
The goal of the new Lawrence facility would be to accumulate as much data as possible to support ongoing and future research into the control and eradication of infectious, rare and oncological diseases.
“We believe we need to be the agent of change that we want to see in the world. With this imprint, we aim not only to support the life sciences industry that seeks to make an impact to support therapeutic discoveries for under-represented populations, but also support our own efforts to bring trust and effective first-hand treatments to the communities we serve, ”added Swift.
Rubix is now working with the Lawrence Economic Development Authority, Massachusetts Development Authority, and Boston-based architecture and interior design firm TRIA to build the new facility, including the workspaces inside.